Psychiatrist-led treatment of hepatitis C (HCV) at an opioid agonist treatment (OAT) clinic in Stockholm - enhancing the HCV treatment care cascade
Introduction People who inject drugs (PWID) and opioid agonist treatment (OAT) patients have an increased hepatitis C (HCV) prevalence. Studies among these populations show promising HCV treatment results, which is essential to reach the WHO goal of eliminating HCV as a major public health threat b...
Main Authors: | M. Kåberg, P.-E. Klasa, T. Nordin |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2022-06-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822004680/type/journal_article |
Similar Items
-
Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework
by: Farah Tahsin, et al.
Published: (2022-04-01) -
Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
by: Dobischok S, et al.
Published: (2022-12-01) -
Does HCV treatment completion affect the neurocognitive outcomes in patients on opioid agonist maintenance treatment: A secondary analysis
by: Abhishek Ghosh, et al.
Published: (2025-02-01) -
Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
by: Ashish P. Thakrar, et al.
Published: (2023-02-01) -
Prevalence of alcohol consumption among clients of opioid agonist treatment (OAT) centers in Golestan province, Iran
by: Alireza Noroozi, et al.
Published: (2023-05-01)